华熙生物(688363) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was RMB 1,254,856,278.10, representing a year-on-year increase of 61.57%[4] - The net profit attributable to shareholders for Q1 2022 was RMB 199,750,879.22, reflecting a growth of 31.07% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 182,886,832.30, with a year-on-year increase of 31.21%[5] - The basic earnings per share for Q1 2022 was RMB 0.42, which is an increase of 31.25% year-on-year[5] - Total operating revenue for Q1 2022 reached ¥1,254,856,278.10, a significant increase of 61.5% compared to ¥776,684,991.71 in Q1 2021[19] - Net profit for Q1 2022 was ¥197,645,537.46, representing a 29.9% increase from ¥152,170,016.46 in Q1 2021[20] - Basic earnings per share for Q1 2022 were ¥0.42, compared to ¥0.32 in Q1 2021, reflecting a 31.3% growth[21] - The company reported a total comprehensive income attributable to the parent company of ¥195,064,274.30 in Q1 2022, compared to ¥147,045,720.16 in Q1 2021[21] Expenses and Costs - Research and development expenses totaled RMB 81,481,354.61, marking a significant increase of 109.24% compared to the previous year[5] - Total operating costs for Q1 2022 were ¥1,023,281,689.96, up 72.8% from ¥592,233,529.05 in Q1 2021[19] - Sales expenses for Q1 2022 were ¥566,195,184.91, an increase of 67.4% compared to ¥338,388,391.76 in Q1 2021[19] - Research and development expenses for Q1 2022 totaled ¥81,481,354.61, up 108.9% from ¥38,941,793.02 in Q1 2021[19] Assets and Liabilities - The total assets at the end of Q1 2022 were RMB 7,414,325,260.54, a decrease of 1.19% from the end of the previous year[5] - Current assets totaled ¥3,564,656,223.73, down from ¥3,984,152,562.74 in the previous year[16] - Cash and cash equivalents were reported at ¥1,794,438,949.42, compared to ¥1,806,636,230.61 in the previous year[15] - Inventory increased to ¥810,908,515.48 from ¥709,132,554.50 year-over-year[16] - Total liabilities decreased to ¥1,402,519,214.76 from ¥1,801,280,273.07[17] - The company's equity attributable to shareholders rose to ¥6,012,630,194.31 from ¥5,699,012,395.15[17] - The company's retained earnings as of March 31, 2022, were ¥1,619,716,502.92, up from ¥1,419,965,623.70[17] Cash Flow - The net cash flow from operating activities was negative at RMB -217,169,901.68, indicating a significant change from a positive cash flow of RMB 24,000,000 in the same period last year[5] - Cash flow from operating activities in Q1 2022 was ¥1,424,663,931.36, an increase from ¥853,859,856.92 in Q1 2021[22] - The net cash flow from operating activities was -$217,169,901.68, a decrease from $23,706,569.22 in the previous year[23] - Total cash outflow from operating activities amounted to $1,641,833,833.04, compared to $830,153,287.70 in the same period last year[23] - The net cash flow from investing activities was $181,874,757.66, an improvement from -$282,307,322.37 year-over-year[23] - Cash inflow from financing activities totaled $84,706,642.83, down from $176,940,000.00 in the previous year[24] - The ending balance of cash and cash equivalents was $1,579,318,450.01, a decrease from $1,302,408,536.14 year-over-year[24] - The company reported a significant increase in cash paid to employees, totaling $354,860,218.94, compared to $205,124,538.00 in the previous year[23] - Cash paid for taxes was $237,524,525.95, up from $101,585,373.36 in the same period last year[23] - Cash outflow related to investment activities was $598,977,832.10, compared to $2,339,005,496.80 in the previous year[23] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 38,153[9] - The number of shares held by the top ten unrestricted shareholders includes JPMorgan Chase Bank with 8,116,913 shares and Hong Kong Central Clearing Limited with 4,361,085 shares[12] Other Financial Metrics - The company had a weighted average return on equity of 3.44%, which increased by 0.45 percentage points year-on-year[5] - The company experienced a decrease in credit impairment losses, reporting -¥6,391,541.99 in Q1 2022 compared to -¥12,932,532.52 in Q1 2021[20] - The total assets and owners' equity amounted to ¥7,414,325,260.54 and ¥6,011,806,045.78 respectively in Q1 2022[18] - The company experienced a negative impact of -$5,306,186.70 from foreign exchange fluctuations on cash and cash equivalents[24]